Ocuphire Pharma Inc. Stock
Ocuphire Pharma Inc. Stock
The Ocuphire Pharma Inc. stock is trending slightly upwards today, with an increase of €0.020 (0.620%) compared to yesterday's price.
Our community identified positive and negative aspects for Ocuphire Pharma Inc. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Ocuphire Pharma Inc. stock. On the other hand our users think that "Innovation" could be a problem in the future.
Pros and Cons of Ocuphire Pharma Inc. in the next few years
Pros
?
B****
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Ocuphire Pharma Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Ocuphire Pharma Inc. | 0.620% | -3.106% | -9.827% | 205.284% | 85.493% | -18.538% | -19.171% |
| Actinium Pharmaceuticals Inc. | 6.840% | 31.983% | 15.443% | -35.227% | -24.441% | -84.410% | -83.111% |
| NanoViricides Inc. | 0.870% | -7.200% | -18.310% | -10.078% | 24.731% | -0.855% | -64.933% |
| AnaptysBio Inc | -1.400% | 2.758% | -21.210% | 175.227% | 12.651% | 181.628% | 139.802% |
Comments
Ocuphire Pharma, Inc. (NASDAQ: OCUP) had its price target lowered by analysts at HC Wainwright from $20.00 to $18.00. They now have a "buy" rating on the stock.
Show more
Ratings data for OCUP provided by MarketBeat
Ocuphire Pharma, Inc. (NASDAQ: OCUP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Show more
Ratings data for OCUP provided by MarketBeat
Ocuphire Pharma, Inc. (NASDAQ: OCUP) had its price target lowered by analysts at Alliance Global Partners from $24.00 to $20.00. They now have a "buy" rating on the stock.
Show more
Ratings data for OCUP provided by MarketBeat
